SPARC signs LoI with UCSF and Tiller Therapeutics for pre-clinical oncology asset and associated IP

SPARC to receive 55% equity in Tiller Therapeutics

SPARC announces results from planned interim analysis of PROSEEK Study

SPARC to present clinical data on vodobatinib

Results from the ongoing vodobatinib clinical study are being presented for the second consecutive year at the ASH annual meeting, underlining the promising potential of the drug for the treatment of heavily pre-treated CML

SPARC partners with Visiox for ophthalmic drugs

SPARC will be eligible to receive an upfront payment, milestone payments and royalty on sales, in addition to 10% equity in Visiox

SPARC to licence Biomodifying’s IP

SPARC will pay Biomodifying a percentage of payments received for sublicenses of the licensed IP

SPARC announces positive results from Phase 3 trial of PDP-716

The trial met its pre-specified primary endpoint, demonstrating that PDP-716 dosed once daily is equivalent to Alphagan P 0.1% dosed 3 times a day